Featured post

Jian Zhang, a member of the US Department of Defense medical project review committee since 2004, is the CCP's Candidate of "National Hundred Thousand Talents Project" and Special Expert of the State Council

 Zhang Jian

professor
National-level candidate for the Hundred Thousand Talents Project
0755-88018036
zhangjian@sustech.edu.cn




Introduction to main academic achievements

Zhang Jian, Professor of School of Medicine, Southern University of Science and Technology, Doctoral Supervisor, Dean of Zhicheng Academy, National Candidate of "Hundreds of Thousands of Talents Project", Special Expert of the State Council, National Leading Talents introduced by Shenzhen, Cancer Metastasis of China Anti-Cancer Association Member of the Standing Committee of the Professional Committee and Chairman of the Youth Committee, Vice Chairman of the Translational Medicine Branch of the Chinese Society of Medicine and Biotechnology, Member of the Standing Committee of the Medical Cell Biology Branch of the Chinese Society of Cell Biology, Vice President of Shenzhen Biomedical Promotion Association, Shenzhen Alliance of China Anti-Cancer Alliance Vice-Chairman, who founded the "Longevity and Aging-related Diseases" Key Laboratory of the Ministry of Education and served as the first director, currently serves as a member of the Academic Committee of the Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research and the Academic Committee of the Shenzhen Key Laboratory of Cell Microenvironment. From 2015 to 2017, he served as the associate editor of "Medical Oncology". SCI has published more than 100 articles in total. He graduated from the University of Michigan School of Medicine with a Ph.D., and has been a member of the US Department of Defense medical project review committee since 2004. Since 2009, he has been a Changjiang Scholar of the Ministry of Education and a final review expert of the Natural Science Foundation of my country. In 2012, he was selected as "National Outstanding Scientific and Technological Worker", and in 2013, he was selected as "National Hundred Thousand Talents Project" and "National Young and Middle-aged Experts with Outstanding Contributions". In 2016, it was approved as "Shenzhen Introduces National Outstanding Talents". Main research directions: aging basis and intervention; tumor microenvironment and metastasis.

 

Research areas

Oncology Translational Medicine Research

Tumor drug resistance, recurrence and metastasis

Aging and Cancer

 

educational experience

1981-1986: Bachelor, Department of Clinical Medicine, Tianjin Medical University

1997-1998: M.S., Immunology, Old Dominion University & East Virginia Medical School

1998-2001: Ph.D., Pathology, University of Michigan

 

main working experience

1986.8-1995.1 Tianjin Third Hospital/Tianjin Institute of Geriatrics, Internal Medicine Resident, Attending Physician

1995.1-1996.8 Visiting Scholar, World Health Organization Fellowship, Institute of Geriatrics, University of Wisconsin-Madison, USA

1996.8-1998.8 Visiting Research Scientist, Eastern Virginia Medical College Geriatrics Research Center

1998.8-2004.6 Ph.D. student/researcher, University of Michigan School of Medicine

2004.7-2010.12 Assistant Professor at University of Pittsburgh and University of Michigan School of Medicine (Tenure track)

2011.1-2016.7 Ministry of Education Key Laboratory of Longevity and Age-related Diseases/Director/Professor of Guangxi Medical University Translational Medical College

2016.3- Adjunct Professor, University of Pittsburgh School of Medicine

2016.7- Professor, School of Medicine, Southern University of Science and Technology

 

honor

2019-Vice President of Shenzhen Biomedical Promotion Association

2018- Vice Chairman of Shenzhen Alliance of China Cancer Prevention and Control Alliance

2014- Obtained the Special Government Allowance Expert of the State Council

2013-Selected as a national candidate for the National Hundred Thousand Talents Project and won the honorary title of "Young and Middle-aged Experts with Outstanding Contributions"

2013-International lecturer certificate issued by American Society for Basic Urological Research (SBUR)

2012-National Outstanding Scientific and Technological Workers

2011-Bagui Scholar of Guangxi Autonomous Region, Counselor of Guangxi Autonomous Region Government

2007-Mentoring Dr. Yi Lu, Young Investigator Travel Award, ASBMR

2005-Mentoring Dr. Yi Lu, Scholar-in-Training Award, AACR

2003-Scholar-in-Training Award, AACR

2003- Plenary Poster Award of 25th Annual Meeting of American Society for Bone and Mineral Research

2002-Alice L. Jee Memorial Young Investigator Award

2000-Plenary Poster Award of 22 nd Annual Meeting of American Society for Bone and Mineral Research

1994- Fellowship Award, World Health Organization (WHO)

 

representative works

  1. Zhang J , Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235-1244, 2001.
  2. Zhang J , Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Antioxidant & Redox Signaling . 3:493-504, 2001.
  3. Zhang J , Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256- 1263, 2002.
  4. Zhang J , J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone. Cancer Res. 63:7883-90, 2003
  5. Zhang J , Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo. Prostate. 59:360-9, 2004
  6. Zhang J , Dai J, Lu Y, Yao Z, O'Brein C, Qi W, Hall D, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. Experimental Gerontology. 39:239-247, 2004
  7. Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J*. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 66:1311-8, 2006
  8. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J*. Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption. Cancer Res, 67:3646- 53, 2007
  9. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, and Zhang J*.    CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 101:676-685, 2007
  10. Lu Y, Yao Z, and Zhang J*. Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment. Chin J of Biochem and Molecul Biol , 23(3):167-171, 2007
  11. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J*. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.   Int J of Cancer. 121:724-733, 2007
  12. Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J*. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation . Mol Cancer Therapeutics, 7(10):3203-11, 2008
  13. Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, and Zhang J*. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res, 6( 4): 546-54, 2008
  14. Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, and Zhang J*. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2): 161-9, 2009
  15. Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, and Zhang J*. MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia , 11(3):228-236, 2009
  16. Zhang J, Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1):41-8, 2010
  17. Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J Natl Cancer Inst. 102(8):522-8, 2010
  18. Zhang J*, Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011
  19. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (CC motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.
  20. Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET, Zhang J*, Deng J*, Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. Plos One . 9( 6):e100394, 2014
  21. Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J *. Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer , 2014, 5; 473-86
  22. Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou* , and Zhang J* . Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759 -7714.12294
  23. Yu Zhu, Chunlin Zou, Zhe Zhang, Chaonan Qian, Xin Yang, Junlin Shi, Yudui Xia,   Zhang J* , Yi Lu*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression . Tumor Biology , 2015, 36(11):8811-8.
  24. Sha He, Yi Lu, Xia Liu, Xin Huang, Evan Keller, Chao-Nan Qian * ,   Zhang J * ; Wnt3a: function and implication in cancer. Chinese Journal of Cancer , 2015, 34(3):50.
  25. Lihui Wang, Yanli He, Weijun Liu, Shengbin Bai, Lei Xiao, Jie Zhang, Saravana M. Dhanasekaran, Zhuwen Wang, Shanker Kalyana-Sundaram, O. Alejandro Balbin, Sudhanshu Shukla, Yi Lu, Jules Lin, Rishindra M. Reddy, Philip W. Carrott, Jr., William R. Lynch, Andrew C. Chang, Arul M. Chinnaiyan, David G. Beer*, Zhang J *, Guoan Chen*. Non-coding RNA LINC00535 promotes lung adenocarcinoma progression via the Akt pathway . Oncotarget, 7(10):11487-99, 2016.
  26. Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lu*, Zhang J* . Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology , 2016, 49:838-846.
  27. Yeguo Yang, Yi Lu, Lihui Wang, Atsushi Mizokami, Evan T. Keller, Zhang J* , Jiejun Fu*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27. Oncology Reports , 2016, 36: 559-566.
  28. Yang Liu, Yi Chai, Zhang J * , and Junwei Tang * . A function variant at miR-501 alters susceptibility the patocellular carcinoma in a Chinese han population. Cell Physiol Biochem, 38(6):2500-8, 2016.
  29. Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J , Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget , 2016, Oct 18;7(42) :68140-68150.
  30. Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer , 2017; 36(1): 17.
  31. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D*, Deng J*, and Zhang J* . Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep . 2017; 7: 41656.
  32. Wenchu ​​Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* and Jian Zhang* . Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer , 2017; 36:35
  33. Yutao Gao, Xia Liu, Ting Li, Luwei Wei, Antai Yang, Yi Lu, Jian Zhang, Li Li, Sumei Wang and Fuqiang Yin. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncology Reports. 2017
  34. Jinlu Dai, Yi Lu, Hernan Roca, Jill M. Keller, Jian Zhang , Laurie K. McCauley and Evan T. Keller. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer , 2017; 36:29

Links to orginal content: 
1. https://www.sustech.edu.cn/zh/faculties/zhangjian.html
2. https://med.sustech.edu.cn/faculty/detail/id/187.html?lang=zh-cn

Comments